Our newest Community Voice Report was made with the Global Pericarditis Support Group. Thank you to everyone who participated....
In the wake of the COVID-19 crisis, different entities around the world are trying to minimize the amount of time it takes to get critical information. One promising endeavor is the COVID-19 Evidence Accelerator....
In February 2020, we presented a poster at NIH Day during Rare Disease Week on Capitol Hill titled: Insights From Closed Social Networks Advance the Understanding of Commonalities Between Rare Diseases. ...
Our newest Community Voice Report was made with the help of an awesome international community. Thank you to everyone who participated. ...
TREND is excited to announce the fact that biopharmaceutical company, Kiniksa, has received Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis....
TREND's newest CVR is now available. ...
Stay up to date with our posts.
Subscribe to our newsletter now!
